ResearchMoz

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

GBI Research
Published Date » 2013-08-30
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs.  
   
 Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Etiology and Pathophysiology
2.2 Classification
2.3 Epidemiology
2.3.1 The US
2.3.2 Obesity in the Top Five European Markets
2.3.3 Japan
2.4 Comorbidities
2.4.1 Type 2 Diabetes
2.4.2 Hypertension
2.4.3 Dyslipidemia
2.4.4 Respiratory Problems
2.4.5 Osteoarthritis
2.4.6 Cancer Risk
2.5 Economic Burden
2.6 Current Therapy Options
2.6.1 Lifestyle and Behavioral Modifications
2.6.2 Bariatric Surgery
2.6.3 Pharmacotherapy
2.6.4 Treatment Algorithms and Prescription Habits
2.6.5 Method of Determining Treatment Effectiveness
2.7 Why Develop Therapeutic Anti-obesity Drugs?
2.8 GBI Research Report Guidance

3 Marketed Products
3.1 Amphetamine-like Drugs
3.1.1 Overview
3.1.2 Efficacy Profile
3.1.3 Safety Profile
3.2 Qsymia, Vivus, Inc.
3.2.1 Overview
3.2.2 Efficacy Profile
3.2.3 Safety Profile
3.2.4 Discussion
3.3 Orlistat
3.3.1 Overview
3.3.2 Efficacy Profile
3.3.3 Safety Profile
3.3.4 Discussion
3.4 Belviq, Arena Pharmaceuticals
3.4.1 Introduction
3.4.2 Efficacy Profile
3.4.3 Safety Profile
3.4.4 Discussion
3.5 Low Long-term Success Rate of Marketed Anti-Obesity Drugs
3.6 Discussion

4 Pipeline
4.1 Overview of Pipeline by Phase, Molecule Type and Molecular Target
4.2 Clinical Trial Duration and Size
4.2.1 Clinical Trial Duration
4.2.2 Clinical Trial Size
4.3 Clinical Trial Failure, Attrition Rate and Reasons for Clinical Trial Failure
4.4 Primary and Secondary Endpoints
4.5 Late-stage Drugs of the Developmental Pipeline
4.5.1 Contrave, Orexigen Therapeutics
4.5.2 Cametor, Norgine BV
4.5.3 Victoza, Novo Nordisk
4.5.4 Tesofensine (NeuroSearch)
4.6 Discussion

5 Market Forecasts
5.1 Global Market
5.2 The US
5.2.1 Epidemiology and Treatment Usage Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Europe
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Discussion
5.6 Drivers and Barriers of the Anti-obesity Market
5.7 Obesity Market Drivers
5.7.1 Obesity is a Very Prevalent Disease with Large Potential Target Populations Globally
5.7.2 Recent Approval of Qsymia to Drive Market Growth Providing its Long-term Safety is Proved
5.7.3 Diversification of Molecular Targets
5.8 Obesity Market Barriers
5.8.1 Low Treatment Rate
5.8.2 Reimbursement Issues

6 Licensing and Co-Development Deals
6.1 Licensing Deals
6.1.1 EMD Serono Enters into Collaboration and Licensing Agreement with Theratechnologies
6.1.2 Amylin Pharma Enters into Licensing Agreement with Takeda Pharma
6.1.3 Palatin Technologies Extends License Agreement with AstraZeneca
6.1.4 Zealand Pharma Enters into Licensing and Collaboration Agreement with Boehringer
Ingelheim
6.2 Co-development Deals
6.2.1 Isis Enters into Collaboration Agreement with Ortho-McNeil
6.2.2 Orexigen Therapeutics Enters into Co-development Agreement with Takeda Pharma for
Contrave

7 Appendix
7.1 References
7.2 Abbreviations
7.3 All Pipeline Drugs by Phase
7.3.1 Discovery
7.3.2 Preclinical
7.3.3 Phase I
7.3.4 Phase II
7.3.5 Phase III
7.3.6 Pre-Registration
7.4 Market Forecasts to 2019
7.4.1 Global
7.4.2 The US
7.4.3 UK
7.4.4 France
7.4.5 Germany
7.4.6 Italy
7.4.7 Spain
7.4.8 Japan
7.5 Methodology
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Pipeline Analysis
7.11 Contact Us
7.12 Disclaimer

List of Tables


Table 1: BMI Classifications
Table 2: Key Components of Pathways Thought to be Related to Obesity
Table 3: Treatment Options Dependent on BMI
Table 4: Obesity Therapeutics, Leading Brand Names of Phentermine
Table 5: Efficacy Results* for Qsymia at 52 Weeks
Table 6: Changes in Key Safety Parameters in Patients Treated with Qsymia
Table 7: Sales Data for Xenical ($m), 2008–2011
Table 8: Efficacy Results for Orlistat as an Initial and Maintenance Therapy
Table 9: Safety Results of Orlistat
Table 10: Efficacy Results for Belviq
Table 11: Placebo-adjusted Safety Results for Belviq
Table 12: Obesity Therapeutics Market, Global, Common Molecular Targets in the Obesity Pipeline
Table 13: Obesity Therapeutics Market, Global, Average Clinical Trial Size for the Most Common Modes of
Action Amongst Pipeline Drugs, 2006–2013
Table 14: Obesity Therapeutics Market, Global, Average Clinical Trial Duration for the Main Modes of
Action Amongst Pipeline Drugs, 2013
Table 15: Contrave, Phase III Clinical Trial Results
Table 16: Contrave, Efficacy Results, Phase III Clinical Trial
Table 17: Cametor, Efficacy Results of a Phase II Clinical Trial
Table 18: Cametor, Safety and Efficacy Results, Phase III Clinical Trial
Table 19: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 20: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009
Table 21: Victoza ,Safety and Efficacy Results, Phase III Clinical Trial, 2009
Table 22: Obesity Therapeutics Market, Europe, Current Prevalence Rate of the Population Which is
Obese or Overweight, 2012–2019
Table 23: Obesity Therapeutics Market: Global, Developmental Pipeline, Discovery Phase
Table 24: Obesity Therapeutics Market: Global, Developmental Pipeline, Preclinical Phase
Table 25: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase I
Table 26: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase II
Table 27: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase III
Table 28: Obesity Pharmacotherapy Market: Global, Developmental Pipeline, Pre-Registration
Table 29: Obesity Therapeutics Market, Global, Market Forecasts, 2012–2019
Table 30: Obesity Therapeutics Market, US, Market Forecasts, 2012–2019
Table 31: Obesity Therapeutics Market, UK, Market Forecasts, 2012–2019
Table 32: Obesity Therapeutics Market, France, Market Forecasts, 2012–2019
Table 33: Obesity Therapeutics Market, Germany, Market Forecasts, 2012–2019
Table 34: Obesity Therapeutics Market, Italy, Market Forecasts, 2012–2019
Table 35: Obesity Therapeutics Market, Spain, Market Forecasts, 2012–2019
Table 36: Obesity Therapeutics Market, Japan, Market Forecasts, 2012–2019

List of Figures


Figure 1: Obesity, Global, Prevalence (%), 1990–2010
Figure 2: Effects of Topiramate on Food Intake
Figure 3: Obesity Therapeutics Market, Obesity Drug Approvals and Market Removals
Figure 4: Obesity Therapeutics Market, Heat Map Comparing the Safety and Efficacy of Marketed Drugs
Figure 5: Obesity Therapeutics Market, Heat Map Comparing the Performance of Marketed Drugs in
Major Safety Parameters
Figure 6: Obesity Therapeutics Market, Global, Pipeline by Phase and Molecule Type and Molecular
Target
Figure 7: Obesity Therapeutics Market, Global, Clinical Trial Duration by Phase and Molecule Type, 2006–
2013
Figure 8: Obesity Therapeutics Market: Global, Clinical Trial Size by Phase and Molecule Type, 2006–2013
Figure 9: Obesity Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Phase and
Molecule Type, 2006–2013
Figure 10: Obesity Therapeutics Market, Global, Clinical Trial Primary and Secondary Endpoints, 2006–2013
Figure 11: Heat Map Comparing the Safety and Efficacy of Marketed and Key Pipeline Drugs
Figure 12: Heat Map Comparing the Performance of Marketed and Key Pipeline Drugs in Major Safety
Parameters
Figure 13: Obesity Therapeutics Market, Global, Epidata and Market Forecasts, 2012–2019
Figure 14: Obesity Therapeutics Market, US, Epidata and Market Forecasts, 2012–2019
Figure 15: Obesity Therapeutics Market, Europe, Treatment Patterns, 2012–2019
Figure 16: Obesity Therapeutics Market, Europe, Annual Cost of Therapy, 2012–2019
Figure 17: Obesity Therapeutics Market, Europe, Market Forecasts, 2012–2019
Figure 18: Obesity Therapeutics Market, Japan, Epidata and Market Forecast, 2012–2019
Figure 19: Obesity Therapeutics Market, Global, Status, Value and Number of Licensing Deals, 2006–2013
Figure 20: Obesity Therapeutics Market, Global, Licensing Deals by Phase, Molecule Type and Value, 2006–
2013
Figure 21: Obesity Therapeutics Market, Global, Status, Value and Number of Co-development Deals,
2006–2011
Figure 22: Obesity Market, Global, GBI Research Market Sizing Model

Upcoming Reports:

Multi-Parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Multiparameter patient monitors are referred as monitoring systems that measure and display numerical data and waveforms for patient. These are parameters obtained through monitoring systems used for the diagnosis and treatment of patients in various healthcare departments. These monitoring devices are used to display signals of various vital signs such as respiratory rate, heart rate, temperature, ECG, blood pressure and others. These devices work by converting electrical signals into readable form that is shown on the monitors display. Global multiparameter patient...
Cholesterol Lowering Nutraceuticals Ingredient Market: Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2009 - 2018
By - Transparency Market Research
Nutraceuticals are defined as the food and dietary substances which help lower the TC (total cholesterol) levels of the body. It functions by triggering the cholesterol inhibiting hormones of the body and thereby restoring homeostasis and preventing coronary heart diseases. Nutraceuticals are currently preferred more than general cholesterol lowering medications. The cholesterol lowering nutraceuticals ingredient market bears two major segmentations, on the basis of types into: beta glucans, soluble fibers, omega 3 fatty acids, plant sterols, soy foods and others, and on the basis...
Neurometabolic Disorder Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
A Neurometabolic disorder is a group of individually rare and progressive disorders limited to symptomatic patient care. The analytical and clinical research result predicts significant development in explaining the molecular genetics, biochemical irregularities, pathogenesis of this disorder and diagnostic testing. The major symptoms of neurometabolic disorders are caused by progressive destruction of mental, motor and perceptual functions. These disorders also include seizures and loss of function associated with early death (before adulthood). Neurometabolic disorders primarily...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Low Gas Prices Hurt Utahs Energy Industry
Dec 18, 2014  
Due to excessive petroleum on the global market, gas prices are heavily tumbling in several places of the world. This aspect could prove effective and great for consumers in most parts of the world, but it is not so for the Utah. The petroleum industry in Utah has a tough time with the state budget.  In Utah, the average gas prices have declined to around $2.64 a gallon. This has...
The 3 Dining Trend to Look Out For in 2015
Dec 17, 2014  
Dining is a vibrant, dynamic subject. You can never set down a list of definitive rules for it, and since it depends on our own fickle taste, it is always subject to drastic changes and welcoming to new trends. Here’s a list of dining trends that are on the cusp of becoming mainstream and will surely make that step up in the coming year. 1. Increasing Acceptance of Technology:...
Bolivian Air Force Receives the Super Puma Helicopters
Dec 16, 2014  
It was declared by the Airbus Helicopters that the Bolivian Air Force was the recipient of second of the six Airbus AS332 C1e Super Puma helicopters. The Super Pumas are generally used for several internal security missions and counter narcotics. The rest of the four helicopters will start operating from the year 2016. In late 2013, the light medium helicopters were purchased by the FAB for...
Leaked Emails Prove to be Challenging for Sony
Dec 15, 2014  
It has been revealed via leaked emails that there exists a cultural gulf between Sony Pictures Entertainment, the Hollywood subsidiary on the one hand and Japan’s Sony Corp on the other. This poses a major challenge to the CEO Kazuo Hirai to bring about positive changes in the loss making company under the One Sony slogan.  Over the past six years, this has been the fifth...
British Construction Firms to Hire More by 2015
Dec 10, 2014  
As per the latest survey carried out by Manpower, increasing workload in Britain’s construction industry is calling for rise in employment opportunities. It is expected that in the coming year, various construction firms will be on a hiring spree. Paucity of trained and skilled workers in U.K. based building firms has led to greater focus on hiring of Portuguese bricklayers at a wage...